Hereditary cancer
Identify how your patient’s genetics may facilitate preventative interventions and early detection, as well as recognize at-risk family members.
sequence once, query often®
TURNAROUND
Existing Patient (SOQO)Ⓡ≤ 5 days
TURNAROUND
New Patient6-21 days
SAMPLE
Saliva, Blood, Buccal
One comprehensive test provides clinical answers today and enables future queries as science evolves.
Clinical Utility
Identifies individuals with a hereditary predisposition to cancer who may benefit from:
- Increased cancer screening
- Risk-reducing surgeries
- Chemoprevention
- Targeted therapies (e.g., PARP inhibitors)
- Clarification of risk for family members
TECH SPECS
Methodology
Exome+® NGS (exome capture + deep intronic coverage in key regions + relevant promoters and inversions).
Accuracy
> 99.9% analytical sensitivity for SNVs and small indels.
CNV resolution
Single exon-level resolution for deletions and duplications.
Wayfinder™ interpretation
Automated pathogenicity score recommendations powered by AI intelligence, augmented by > 850k longitudinal records.
Helix cancer panels comparison
View a full comparison of all Helix Hereditary Cancer tests here:
Helix Cancer PanelsTest Catalog
Select a test below to view a detailed test description, technical specifications and complete gene list.
Hereditary Comprehensive Cancer Panel
A comprehensive 70-gene panel for assessing hereditary risk across breast, gynecologic, colorectal, pancreatic, prostate, kidney, skin, brain, and endocrine cancers, powered by the Helix Exome+® platform.
70
genesHereditary Breast and Gynecologic Cancers Panel
A 21-gene panel for assessing hereditary risk for breast, ovarian, and uterine cancers, powered by the Helix Exome+® platform for comprehensive variant detection.
21
genesHereditary Breast Cancer Panel
A focused 13-gene panel for evaluating hereditary breast cancer predisposition, powered by the Helix Exome+® platform for superior coverage of clinically relevant regions.
13
genesHereditary Colorectal Cancer Panel
A 19-gene panel for evaluating hereditary predisposition to colon polyps and colorectal cancer, powered by the Helix Exome+® platform for enhanced clinical accuracy.
19
genes